查看文章

Background

Mitotane is the cornerstone of both adjuvant and metastatic treatment of adrenocortical carcinoma (ACC). The side effects of this drug include those related to its estrogenic mimetic action, which has not been well studied.

Methods

We conducted a retrospective study to assess the rate of menometrorrhagia, endometrial thickness, and ovarian cysts among female ACC patients (F-ACC), as well as gynecomastia among male ACC patients (M-ACC patients) who had been taking mitotane for at least 6 months. Secondary objectives were to examine the correlation between these toxicities and possible clinical factors.

Results

35 F-ACC and 25 M-ACC patients were enrolled; of these, 22 (36.7%) F-ACC and 7 (11.7%) M-ACC patients developed mitotane-related estrogenic effects, respectively. Among F-ACCs, 10 (28.6%) had menometrorrhagia, 8 (22.9%) endometrial thickening, and 13 (37.1%) ovarian cysts …